AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

AbCellera has entered into a collaboration with Vertex Pharmaceuticals to discover and develop multispecific T-cell engagers for autoimmune diseases and other conditions. Under the agreement, AbCellera will lead discovery and early development using its proprietary TCE platform. Vertex will fund all research and development costs and retain rights to develop and commercialize the resulting therapies. AbCellera receives $28 million in upfront payments and is eligible for future milestones and royalties.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.